盲式解卷降低了对DCE-MRI时间分辨率的要求:适用于第二代药理动力学建模的应用
Jiří Kratochvíla1, Radovan Jiřík1, Michal Bartoš2
1Czech Academy of Sciences, Institute of Scientific Instruments, Královopolská 147, 612 64 Brno, Czech Republic.
Magnetic resonance imaging
|March 20, 2024
概括
盲目的解卷减少了动态对比增强MRI (DCE-MRI) 中第二代药理学模型的时间分辨率需求. 这允许在成像研究中获得更高的空间分辨率或更大的器官覆盖.
科学领域:
- 医疗成像医学成像
- 药理动力学 药理动力学
- 生物物理学的生物物理.
背景情况:
- 动态对比增强MRI (DCE-MRI) 与第二代药理动力学模型提供了对血流量和透性的先进见解.
- 这些模型,与第一代模型不同,需要更高时间分辨率的成像 (约. 每张图像的时间为1.5秒).
- 盲视解卷技术此前已经显示出降低第1代模型的时间分辨率需求的潜力.
研究的目的:
- 在DCE-MRI中与第二代药理动力学模型一起应用时,调查盲目解卷的时间分辨率要求.
- 评估降低通常与先进的DCE-MRI药理动力学建模相关的高时间分辨率需求的可行性.
主要方法:
- 这项研究采用了分布式毛细管附性组织同质性 (DCATH) 模型,这是第二代药理动力学模型.
- 基于帕克的动脉输入函数模型的盲目解卷被使用.
- 动脉输入功能的准确性和精度和 perfusion 参数使用合成和真实临床 DCE-MRI 数据集在不同的时间分辨率进行了评估.
主要成果:
- 动脉输入功能的估计保持稳定,在合成数据的采样间隔为~5s,在真实数据的采样间隔为~3.6-4.8s.
- 超出这些点的采样间隔增加导致了第一通峰的扭曲.
- 输液参数估计误差在采样间隔高达3s (合成) 的情况下低于10%,在真实数据中保持一致,高达3.6s.
结论:
- 盲点解卷显著降低了第二代DCE-MRI模型的时间分辨率要求,从约1.5秒到3-4秒.
- 这种减少时间分辨率的需求可以用来提高空间分辨率或扩大DCE-MRI扫描器官覆盖范围.
- 这些发现表明,一种实用方法可以提高DCE-MRI中先进的药理动力学建模的效率和实用性.
更多相关视频
11:28Concurrent EEG and Functional MRI Recording and Integration Analysis for Dynamic Cortical Activity Imaging
Published on: June 30, 2018
11.7K
10:25Author Spotlight: Integrating High-Resolution Intravital Imaging and MRI to Enhance Stereotactic Body Radiation Therapy Planning
Published on: April 12, 2024
1.4K
相关概念视频
01:26Pharmacokinetic Models: Comparison and Selection Criterion
Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
01:24Pharmacokinetic–Pharmacodynamic Relationship: Problems
The empirical approach to drug therapy optimization relies on correlating pharmacological response with administered dosage. Such an approach can be costly, time-consuming, and often yields poor correlation due to variables like formulation factors and drug elimination characteristics. A more precise approach correlates response with plasma drug concentration or the amount of drug in the body, rather than dosage. This is achieved through pharmacokinetic-pharmacodynamic (PK/PD) modeling, which...
01:27Pharmacodynamic Models: Overview
Pharmacodynamic (PD) responses describe the interaction between a drug and its biological target, culminating in a physiological effect. These responses can be classified into different types: continuous variables, such as blood glucose levels; categorical outcomes, like survival rates; and time-to-event metrics, such as disease progression. Understanding and modeling PD responses are critical for optimizing drug efficacy and safety.PD models describe the relationship between drug concentration...
01:18Pharmacodynamic Models: Emax Drug–Concentration Effect Model
The Emax drug-concentration effect model is central to pharmacodynamics in drug discovery and development. This model is predicated on the receptor occupancy theory, which posits that the effect of a drug is directly related to the number of receptors occupied by the drug and the resultant complex formation.The model describes the reversible interaction between a drug (C) and a receptor (R) to form a drug-receptor complex (RC). The kinetics of this interaction are quantified by an equation that...
01:15Pharmacodynamic Models: Linear Concentration–Effect Model
The linear concentration–effect model, underpinned by the principle that pharmacological effect (E) is directly proportional to plasma drug concentration (C), emerges as a pivotal simplification of the Emax model for conditions where C is significantly less than EC50. This model portrays a linear trajectory of the concentration–effect relationship when drug levels are markedly below the EC50 threshold.Despite its inherent assumption of continuous effect augmentation with increasing drug...
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).